Research use onlyNot for human or veterinary use
Encore Bio Labs CartExplore catalog
ENCORE BIO LABSRESEARCH COLLECTION
PT-141 — complete Encore Bio Labs reference vialMATERIAL / 16

Reference artwork · Legacy packaging may be shown.
Listed identity and formats take precedence over the image.

Research material

PT-141

A ring-shaped peptide with receptor signaling at its center. PT-141 is the development name associated with bremelanotide, whose reference pharmacology involves several melanocortin receptors. Its distinctive shape and receptor profile invite a closer look at the connection between peptide design and biological signals.

CAS
189691-06-3

Formats & reference pricing

USD
Listed formatReference price
10 mg$50 USD

Reference prices describe the listed formats. They do not confirm availability or constitute an offer for sale.

Review product documentation

For laboratory research only. Not for human or veterinary use.

About the reference identity

A development code and a cyclic structure

PT-141 is a development code associated with the name bremelanotide. Its reference structure contains seven amino-acid residues and an internal connection that creates a ring, making it a cyclic peptide. Sequence, ring connectivity and chemical form are separate features used to describe that molecular identity.

Reference synonym
Bremelanotide
Reference structure
Seven residues with a cyclic connection

Reference identity only; not a test result for current inventory.

01 / Material overview

The specifications.

Catalog identity
PT-141
CAS
189691-06-3
Listed formats
10 mg
Reference price range
$50 USD
Intended setting
Qualified laboratory or institutional research
Inventory specifications
Independent inventory review pending

02 / Public regulatory context

Approved product and catalog boundaries.

Public FDA labeling can identify an approved prescription product containing bremelanotide. It does not establish approval or equivalence of this PT-141 catalog material.

REGULATORY REFERENCE · STATUS REVIEWED OCT 2026PT-141 / BREMELANOTIDE

An FDA-approved branded product exists. This catalog material is separate.

VYLEESI is an FDA-approved prescription drug product containing bremelanotide. This Encore Bio Labs PT-141 catalog listing is not represented as VYLEESI, FDA-approved, interchangeable, substitutable, or equivalent in formulation, sterility, potency, manufacturing controls, quality, or intended use.

Catalog identity
PT-141
Related public name
Bremelanotide
CAS
189691-06-3
FDA-labeled product
VYLEESI
Catalog approval status
Not represented as an FDA-approved drug product
Approved-product equivalence
Not represented or established
Scope of this reference

The approved-product record is linked only to distinguish public regulatory information from this catalog listing. It is not reproduced as consumer indication, sexual-performance, dosing, injection, preparation, administration, personal-use, or medical guidance for this material.

External public records

DailyMed · VYLEESI / bremelanotide label

03 / Supporting records

Documentation.

Read the Encore summary, the scope of related reports and the status of privacy-redacted supplier copies.

No authenticated certificate establishing current-inventory identity or specifications is published for PT-141 in this catalog.

Encore documentary summary · not a laboratory-issued COA

View PT-141 PDF downloads ↓
Report availability
1 related report located
Formats & scope
A related sample is labeled PT-141 10 mg.
Report authenticity
Laboratory authentication pending
Inventory evidence review
Report-to-inventory correspondence has not been independently established. No purity, quantity or activity result is attributed to current inventory.
Outstanding review
Review report authenticity and the relationship between the tested sample and supplied material.
Product-specific SDS
Not located in the reviewed PDF set; applicability and verification pending.

Document inventory reviewed October 6, 2026. Related reports were commissioned by third parties, not Encore. Original customer details and internal records are not included here.

Privacy-redacted supplier report

Supplier-provided laboratory report

Where prepared, these are copies redacted by Encore for privacy, not laboratory-issued public versions or Encore-commissioned tests. Analytical content is not replaced with Encore results.

PT-141 · Related reports

1 report · PDF available

English original · 2 pages · 0.3 MB

Open PDF Download PDF

Spanish translation · 4 pages · 0.3 MB

Open Spanish PDF Download Spanish PDF

Open PDF uses a new tab. Download PDF saves the same privacy-redacted packet.

Prepared by Encore; not issued or certified by the laboratory. Each translated page is followed by its English source page, preserving original graphs and signatures. The separate English original is unchanged.

Included scope and exclusions: The selected report names a PT-141 10 mg sample. Matching the name and nominal format does not establish report authenticity, current-stock contents or inventory correspondence.

Laboratory authentication pending. These related references are not independently authenticated certificates for current Encore inventory. Supplier confirmation does not resolve the scope or discrepancies listed above.

Copy preparation
1 source file in redacted review copies. Duplicate file formats are not additional tests.
Supplier sharing permission
Owner-confirmed for supplied reports; this does not imply a report exists for every product. Report authentication is a separate check.
Privacy review
Selected website copy redacted; residual identification risk remains. Retained references and copies elsewhere can still identify the original customer; redaction does not guarantee anonymity.
Downloads
Selected related-reference PDF available.
Laboratory-issued public copy
Not available. Encore-prepared redactions are not an issuer reissue.

Read the packet cover and each report’s scope and limitations. Outstanding review items above remain unresolved; PDF availability does not change verification status.

A public copy does not by itself verify current inventory. No laboratory replacement or delivery date is promised.

Explore summary & report status

04 / A closer look

Common questions.

01Which PT-141 formats and reference prices are listed?

10 mg: $50 USD. These are catalog quantities and reference prices, not usage instructions, stock confirmation or an offer for sale.

02Where can I find the PT-141 reports?

The Documentation section on this page includes Open PDF and Download PDF links to a 2-page English original containing 1 supplier-provided report. Read the covered sample formats and limitations beside the download. These privacy-redacted, third-party-commissioned copies are not laboratory reissues. Laboratory authentication and independent inventory review remain pending.

03Is this catalog material VYLEESI?

No. FDA-approved VYLEESI contains bremelanotide, but this PT-141 catalog material is not represented as VYLEESI, as an approved drug product, or as equivalent or substitutable.

04Does VYLEESI prescribing information apply to this catalog material?

No. FDA-approved labeling applies to the specific approved product and formulation described in that labeling. It does not establish the formulation, sterility, potency, manufacturing controls, quality, or intended use of this catalog material.

05Does this page provide sexual-performance, dosing, injection, or administration guidance?

No. This catalog provides no consumer outcome, sexual-performance, dosing, injection, preparation, administration, personal-use, or medical guidance.

06Does the image establish the contents of a lot?

No. The image is owned Encore Bio Labs reference artwork and may show legacy packaging. Use the written identity and specifications, then verify the exact lot with supporting records.

Continue the collection

Next in the catalog.

View all materials